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We were delighted to read the Spotlight on invisible suffering. Chronic refractory 
breathlessness [1] affects millions of people worldwide, but is yet to receive the same 
attention, both clinical and research, as the causative conditions. The Spotlight 
resonates strongly with a growing body of work in this field arising from interdisciplinary 
research collaborations between respiratory physicians, physiologists, palliative care 
specialists, nurses, psychologists, neuro-radiologists, geneticists, clinical 
pharmacologists, physiotherapists and sociologists.  
The impact of refractory breathlessness on everyday living is far-reaching, as the 
Spotlight authors suggest. Indeed research found that this distress and limitations are 
often hidden from family, friends and health care professionals. [2]  Meticulous 
observation of clinical and laboratory findings has led to a useful model of 
breathlessness of perception (intensity and unpleasantness), emotional response and 
functional consequences, leading to an emerging delineation of pathophysiological 
pathways, both peripherally and centrally.[3] Such understanding is assisting the 
development of drug (opioids) [1] and non-drug interventions,[4] and markedly 
improved models of delivering care and support to people with refractory 
breathlessness.[5]  We are conducting primary and secondary research to gain further 
insight into patient experience, to investigate the prevalence and role of 
breathlessness in the emergency room and other healthcare settings, to identify 
mechanisms of breathlessness perception evaluate interventions. 
We welcome ‘The life of breath’ programme of Jane McNaughton and colleagues, 
which was presented at our recent multi-professional breathlessness research 
meeting. We agree that there is much still to do. It is timely that a Spotlight is turned 
on chronic refractory breathlessness itself as a target for intervention as well as the 
biomedical cause.  
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